Our Science
EpimAb's Proprietary Bispecific Platform : FIT-Ig®
Pipeline
We have a robust and sustainable pipeline with 3 clinical stage assets (EMB-01, EMB-06 and EMB-07) and more than 10 preclinical stage candidates. Our proprietary FIT-Ig® platform and other technical capabilities enable us to target three strategic oncology areas (tumor targeting, dual checkpoint inhibitors, immune cell engagers) and maintain our strong momentum to advance additional preclinical assets to the clinic.
EMB-02
PCC
IND-
Enabling
Enabling
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
News
2026-04-15
EpimAb Biotherapeutics to Present a Novel Prodrug T-Cell Engager (ProTCE) Platform at the 2026 American Association for Cancer Research Annual Meeting
2026-02-10
EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-Ig® Bispicific Antibody by its License Partner Almirall
2025-05-27
Juri Biosciences, a TCG Labs Soleil Portfolio Company, and EpimAb Biotherapeutics Enter into a Worldwide Licensing Agreement for KLK2-Directed T-Cell Engager in Metastatic Prostate Cancer
Who We Are
EpimAb Biotherapeutics is a clinical stage biopharmaceutical company with research facilities in Shanghai. With our unique and proprietary platform technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that is able to generate bispecific molecules with antibody-like properties, we are creating a pipeline of novel therapeutics focused around immuno-oncology and other disease areas with high unmet need.
Contact
Shanghai
Adress
6th Floor, Building 2, Jinchuang Building, 702 Zhongke Road, Zhangjiang High-tech Park, Shanghai, 201204, China
Phone
Email
contact@epimab.com
shanghai
